anti-Bevacizumab ELISA Kit (Avastin®) (ab237658)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 62 ng/ml - 500 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
anti-Bevacizumab ELISA Kit (Avastin®)
See all Bevacizumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall Inter-assay Sample n Mean SD CV% Overall -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
30 ng/ml -
Range
62 ng/ml - 500 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
anti-Bevacizumab ELISA Kit (Avastin®) (ab237658) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Bevacizumab in biological matrices such as human serum and plasma.
Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. It has been demonstrated that bevacizumab, in combination with chemotherapy, resulted in increased survival in patients with previously untreated metastatic colorectal cancer relative to chemotherapy alone, leading to FDA approval of the first antiangiogenic agent. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Micro ELISA Plate 1 unit Bevacizumab standard 1 1 x 1ml Bevacizumab standard 2 1 x 1ml Bevacizumab Standard 3 1 x 1ml Bevacizumab Standard 4 1 x 1ml Bevacizumab Standard 5 1 x 1ml Bevacizumab Standard 6 1 x 1ml Bevacizumab Standard 7 1 x 1ml Assay Buffer 1 x 50ml Confirmation Reagent 1 x 12ml Peroxidase Conjugate 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 tablets -
Relevance
Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
Images
-
Typical standard curve.
Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.
